Latest Regulatory Approval News

Amplitude Energy has delivered record production and earnings in FY25, driven by operational improvements and a strategic joint venture for the East Coast Supply Project.

Amplitude Energy Limited reported a 22% revenue increase to A$268.1 million for FY25, narrowing its net loss significantly while progressing its East Coast Supply Project with a new joint venture partner.

Resouro Strategic Metals launches a CAD 2 million private placement to fund engineering work advancing its Tiros project in Brazil, marking a key step toward a Preliminary Economic Assessment.

CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.

CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.

Platinum Asia Investments Limited (PAI) shares have been suspended following Federal Court approval of a scheme exchanging all shares for units in the Platinum Asia Fund Complex ETF (PAXX). This marks a significant structural shift for PAI investors.

MAC Copper has secured Foreign Investment Review Board approval, satisfying all regulatory conditions for its acquisition by Harmony Gold’s Australian subsidiary. The deal now awaits shareholder votes and court sanction to proceed.

Peak Rare Earths Limited has entered a scheme of arrangement with Shenghe Resources (Singapore) Pte. Ltd., valuing the company at approximately A$158 million. The scheme offers Peak shareholders a cash consideration of no less than A$0.359 per share, representing a 199% premium to the last closing price.

McLaren Minerals reports promising early Phase 1 drilling results at its McLaren Titanium Project, revealing high-grade heavy mineral assays beyond current resource boundaries and signaling strong potential for resource expansion.

Rhythm Biosciences has launched a $3.75 million placement alongside an offer of over 52 million new options, all contingent on shareholder approval. The move aims to bolster working capital as the company advances its cancer diagnostic products.

Bass Oil reported steady oil production in July alongside progress in acquiring the Vanessa gas field and advancing deep coal commercialisation efforts.

Apiam Animal Health has received a non-binding indicative proposal from Adamantem Capital Management to acquire the company at $0.88 per share, sparking a potential shift in ownership for the veterinary services leader.